Researcher, Outstanding Talent of the Guangdong Province "Special Support Program" (Nanyue Bai Jie), National-Level High-Level Leading Talent of Shenzhen, Chief Scientist of the National Key R&D Program, mainly engaged in clinical and applied basic research on urological tumors. Currently, he is the Director of the Discipline Construction Office at Shenzhen Second People’s Hospital, Vice Dean of the School of Translational Medicine, Executive Director of the National and Local Joint Cancer Genomics Clinical Application Key Technology Engineering Laboratory, Deputy Director of the National and Local Joint Medical Synthetic Biology Application Key Technology Engineering Laboratory, Deputy Director of the Guangdong Provincial Key Laboratory of Urological and Reproductive Cancer System and Synthetic Biology, Director of the Shenzhen Key Laboratory of Medical Gene Reprogramming Technology, Vice Chairman of the Synthetic Biology Branch of the China Biopharmaceutical Technology Association, Member of the Urology Branch of the Chinese Medical Association, Member of the Synthetic Biology Committee of the Chinese Society of Biotechnology, and Vice President of the Shenzhen Synthetic Biology Association.
Focusing on the clinical needs of urological tumors, his team continuously strengthens interdisciplinary integration. By combining tumor precision diagnosis and treatment with synthetic biology research, they have developed a tumor high-fidelity 3D organoid construction and application platform using clinical sample-derived tissues, which simulates the real in vivo environment of urological tumors. This model is used to explore precise drug screening, resistance molecular mechanisms, artificial gene circuit synthesis, and engineered immune cell functional evaluation. It provides an efficient in vitro model for functional testing in precision medicine. Focusing on tumor synthetic biology enabling technologies and common scientific issues, they have developed new clinical treatment methods for bladder cancer, conducting research on bladder cancer-specific identification and diagnosis and treatment. By integrating different biological signals, including gene mutations, methylation, and promoter abnormalities, they design artificial gene circuits to accurately distinguish cancer cells from normal cells, reprogram tumor cell fate, and directly kill them. They also develop theoretical foundations for tumor gene circuit design and establish an "integrated" targeted delivery system that matches different types of gene circuits to provide optimal carriers for efficient targeted engineering.
His research provides a rich toolbox for precise identification and intervention in urological tumors and has developed related technical theories, providing an important scientific basis for precision treatment. His work has been published in over 100 international journals, including Nature Methods, Nature Communications, Advanced Science, Genome Biology, ACS Applied Materials & Interfaces, and Clinical and Translational Medicine, receiving high praise from domestic and international peers. As the first author, he has received the China Medical Science and Technology Award and the Shenzhen Natural Science Award and has been granted 14 national invention patents. The development of this research has enriched the theoretical and scientific foundations of tumor synthetic biology technology, improved the precision medicine system for tumors, and established a "design, test, application" closed-loop, which will promote the transition of gene circuit-based tumor synthetic biology therapies from proof-of-concept to clinical application.